Ra Capital Management, a director and more than 10% owner of 89bio Inc. (ETNB), bought common stock worth $49.99 million last ...

These purchases signal continued confidence in 89bio's prospects, as the company continues its work in pharmaceutical preparations. The company maintains a strong balance sheet with more cash than ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock ...

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

abrdn plc reduced its stake in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 30.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC.The fund owned ...

Check Out Our Latest Report on 89bio 89bio Price Performance Shares of ETNB opened at $11.43 on Wednesday. The business’s 50 day moving average price is $7.94 and its two-hundred day moving ...

89bio (NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a ...